...
首页> 外文期刊>Case Reports & Clinical Practice Review >A Case of Diffuse Alveolar Hemorrhage as a Possible Complication of Bivalirudin Therapy
【24h】

A Case of Diffuse Alveolar Hemorrhage as a Possible Complication of Bivalirudin Therapy

机译:一例弥漫性肺泡出血可能是比伐卢定治疗的可能并发症

获取原文

摘要

Objective: Rare complication/diseaseBackground: Diffuse alveolar hemorrhage (DAH) is a rare but potentially fatal complication of anticoagulant or antiplatelet therapy. Bivalirudin is a specific and reversible direct thrombin inhibitor (DTI). Case Report: We report a case of severe DAH, possibly related to bivalirudin use, in a 61-year-old patient undergoing coro- nary intervention. The patient had presented with an out-of-hospital cardiac arrest due to acute ST elevation myocardial infarction (STEMI). During the coronary intervention, shortly after receiving bivalirudin, the patient started having frank bleeding from the endotracheal tube and developed hemodynamic compromise. Despite aggressive intervention and intensive care, the patient died. Conclusions: At this time, to our knowledge, there have been no reports of DAH associated with the use of bivalirudin.
机译:目的:罕见的并发症/疾病背景:弥漫性肺泡出血(DAH)是一种罕见的但可能致命的抗凝或抗血小板治疗并发症。比伐卢定是一种特异性且可逆的直接凝血酶抑制剂(DTI)。病例报告:我们报告了一名61岁接受冠脉介入治疗的严重DAH患者,可能与使用比伐卢定有关。该患者因急性ST抬高型心肌梗死(STEMI)而出现院外心脏骤停。在冠状动脉介入治疗期间,在接受比伐卢定治疗后不久,患者开始从气管内导管明显出血,并出现了血流动力学损害。尽管进行了积极的干预和重症监护,该患者仍然死亡。结论:据我们所知,目前尚无关于比伐卢定使用DAH的报道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号